BELLUS Health Inc.: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei BELLUS Health Inc. listata cu simbolul US.BLU ==Descriere companie== BELLUS Health Inc. (www.bellushealth.com) is a clinical stage pharmaceutical company that is focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate, BLU-5937, is being studied in Phase II clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis. It is developi...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
BELLUS Health Inc. (www.bellushealth.com) is a clinical stage pharmaceutical company that is focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate, BLU-5937, is being studied in Phase II clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis. It is developing BLU-5937 for the treatment of chronic cough and chronic pruritus, or chronic itch. The Company is focused on SOOTHE, which is in a Phase IIb trial of BLU-5937 in refractory chronic cough patients. It is also focused on BLUEPRINT, which is in a Phase II trial in chronic pruritus associated with atopic dermatitis. The RELIEF trial established proof-of-concept for BLU-5937 in the treatment of RCC patients. | BELLUS Health Inc. (www.bellushealth.com) is a clinical stage pharmaceutical company that is focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate, BLU-5937, is being studied in Phase II clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis. It is developing BLU-5937 for the treatment of chronic cough and chronic pruritus, or chronic itch. The Company is focused on SOOTHE, which is in a Phase IIb trial of BLU-5937 in refractory chronic cough patients. It is also focused on BLUEPRINT, which is in a Phase II trial in chronic pruritus associated with atopic dermatitis. The RELIEF trial established proof-of-[[CONCEPT|concept]] for BLU-5937 in the treatment of RCC patients. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||